BR9914419A - Perception improvement therapy - Google Patents

Perception improvement therapy

Info

Publication number
BR9914419A
BR9914419A BR9914419-0A BR9914419A BR9914419A BR 9914419 A BR9914419 A BR 9914419A BR 9914419 A BR9914419 A BR 9914419A BR 9914419 A BR9914419 A BR 9914419A
Authority
BR
Brazil
Prior art keywords
perception
alzheimer
disease
effect
active ingredient
Prior art date
Application number
BR9914419-0A
Other languages
Portuguese (pt)
Inventor
Paul Leonce Irma De Nijs
Wim Louis Julien Prays
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR9914419A publication Critical patent/BR9914419A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Patente de Invenção: <B>"TERAPIA PARA MELHORIA DA PERCEPçãO"<D>. A presente invenção refere-se a composições farmacêuticas, que compreendem um veículo e como um primeiro ingrediente ativo um agente antipsicótico atípico (I) e como segundo ingrediente ativo um inibidor de acetilcolinesterase (II), cada um em uma quantidade que produz um efeito terapeuticamente benéfico em pacientes que sofrem de psicose, de doença de Alzheimer ou de demências correlatas. O dito efeito terapeuticamente benéfico pode ser um efeito sinergístico sobre o funcionamento perceptivo de pacientes que sofrem da doença de Alzheimer ou de demências correlatas ou na prevenção de uma posterior deterioração da percepção nos ditos pacientes ou na redução de efeitos adversos associados a um dos ingredientes ativos através de outro dos ingredientes ativos.Invention Patent: <B> "THERAPY FOR IMPROVING PERCEPTION" <D>. The present invention relates to pharmaceutical compositions, which comprise a carrier and an atypical antipsychotic agent (I) as a first active ingredient and an acetylcholinesterase (II) inhibitor as a second active ingredient, each in an amount that produces a therapeutically effect. beneficial in patients suffering from psychosis, Alzheimer's disease or related dementias. Said therapeutically beneficial effect may be a synergistic effect on the perceptual functioning of patients suffering from Alzheimer's disease or related dementias or in preventing further deterioration of perception in said patients or in reducing adverse effects associated with one of the active ingredients. through another of the active ingredients.

BR9914419-0A 1998-10-16 1999-10-12 Perception improvement therapy BR9914419A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203454 1998-10-16
PCT/EP1999/007804 WO2000023057A2 (en) 1998-10-16 1999-10-12 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition

Publications (1)

Publication Number Publication Date
BR9914419A true BR9914419A (en) 2001-06-26

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914419-0A BR9914419A (en) 1998-10-16 1999-10-12 Perception improvement therapy

Country Status (20)

Country Link
EP (1) EP1121131A2 (en)
JP (1) JP2002527469A (en)
KR (1) KR20010072878A (en)
CN (1) CN1367697A (en)
AU (1) AU6472799A (en)
BG (1) BG105302A (en)
BR (1) BR9914419A (en)
CA (1) CA2345767A1 (en)
EE (1) EE200100136A (en)
HK (1) HK1039745A1 (en)
HR (1) HRP20010262A2 (en)
HU (1) HUP0103781A3 (en)
ID (1) ID28441A (en)
IL (1) IL142588A0 (en)
NO (1) NO20011403L (en)
PL (1) PL348107A1 (en)
SK (1) SK4592001A3 (en)
TR (1) TR200101082T2 (en)
WO (1) WO2000023057A2 (en)
ZA (1) ZA200103081B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
JP5067998B2 (en) 2001-10-30 2012-11-07 ノバルティス アーゲー Depot formulation of iloperidone and star polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
CA2551486A1 (en) * 2003-12-22 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
CA2552221A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
SI2091948T1 (en) 2006-11-30 2012-07-31 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
MX2007008642A (en) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Pharmaceutical composition comprising the combination of a benzisoxazolic derived agent and a reversible inhibiting agent of the cholinesterase enzyme prescribed for the control and treatment of psychotic disorders and dementias.
EA037187B1 (en) 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Method and composition for treating a cognitive disorder
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
JP6050264B2 (en) 2011-03-16 2016-12-21 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins Methods and compositions for improving cognitive function
AU2016268096B2 (en) 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312817A (en) * 1991-05-14 1994-05-17 Ernir Snorrason Treatment of fatigue syndrome
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
JP4640888B2 (en) * 1997-08-11 2011-03-02 ザ ユニヴァーシティー オブ サウス フロリダ Nicotine antagonists for neuropsychiatric disorders
DE1073432T1 (en) * 1998-04-14 2002-02-07 Gen Hospital Corp USE OF GLYCINE RECEPTORAGONISTS AND GLYCINE INHIBITOR INHIBITORS FOR THE TREATMENT OF NEUROPSYCHIATRIC COMPLAINTS

Also Published As

Publication number Publication date
WO2000023057A2 (en) 2000-04-27
NO20011403D0 (en) 2001-03-20
CA2345767A1 (en) 2000-04-27
BG105302A (en) 2001-11-30
TR200101082T2 (en) 2001-09-21
JP2002527469A (en) 2002-08-27
AU6472799A (en) 2000-05-08
EE200100136A (en) 2002-06-17
WO2000023057A3 (en) 2000-07-27
ZA200103081B (en) 2002-07-12
SK4592001A3 (en) 2001-12-03
CN1367697A (en) 2002-09-04
IL142588A0 (en) 2002-03-10
HUP0103781A3 (en) 2003-09-29
PL348107A1 (en) 2002-05-06
EP1121131A2 (en) 2001-08-08
HUP0103781A2 (en) 2002-03-28
NO20011403L (en) 2001-03-20
HK1039745A1 (en) 2002-05-10
ID28441A (en) 2001-05-24
KR20010072878A (en) 2001-07-31
HRP20010262A2 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
BR9914419A (en) Perception improvement therapy
BRPI0414876A (en) pharmaceutical compounds and compositions for the prevention of overdose or abuse and their uses
BRPI0517481A (en) method for treating, controlling or preventing a protozoan parasitic disease or disorder, and, pharmaceutical composition
BR0312286A (en) 2 &#39;and 3&#39; prodrugs - modified nucleoside for treatment of flaviviridae infections
BRPI0418270A (en) methods of treatment and control, treatment or prevention, control of a central nervous system disorder, and to reduce or prevent an adverse effect, and, pharmaceutical composition
TW200718418A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
BR0013122A (en) Cyclobenzaprine for treatment of generalized anxiety disorder and cyclobenzaprine compositions
BR0008059A (en) Compositions of valdecoxib
BR0004884A (en) Acaricidal compositions
ATE360630T1 (en) AZABICYCLIC HETEROCYCLES AS MODULATORS OF THE CANNABINOID RECEPTOR
BR0108930A (en) Method of delivering an active agent to a cell type of interest, pharmaceutical composition, caspase-activated prodrug, kit, method of treating mammals, using a caspase conjugate and using a pro-agent
BRPI0509400A (en) methods for treating or preventing dysfunctional sleep, controlling dysfunctional sleep and improving time to sleep, duration of sleep or quality of sleep, or enhancing ability to get up feeling refreshed after a night&#39;s sleep, pharmaceutical composition , and, kit suitable for use in the treatment, prevention or control of dysfunctional sleep
BR0110420A (en) Muscarinic Agonists
BR9810312A (en) Pharmaceutical composition that has marked antitumor activity and / or reduced side effects containing an antitumor agent and a derivative of hydroxy acid
BR0306919A (en) Methods for reducing or suppressing the adverse effectiveness of l-dopa and / or dopamine agonist therapy, and for moderate l-dopa treatment, composition for moderate l-dopa treatment, method for treating parkinson&#39;s disease and / or complications. -dopa motors, composition for the treatment of parkinson&#39;s disease, and methods for prolonging the effective treatment of parkinson&#39;s disease, and for treating movement disorders
DE60040753D1 (en) THERAPEUTIC USES OF STEROIDS IN BLOOD CELL FAULT EXPOSURES
BR0014946A (en) Use of dipyridamole or mopidamol in the manufacture of a drug for the treatment and prevention of fibrin-dependent microcirculatory disorders
NO20024646L (en) Combination therapies with vasculature-damaging activity
UA92498C2 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
BR0012696A (en) Ophthalmic composition
BR0309057A (en) Low dosage liquid formulations in entecavir and use
BRPI0413404A (en) pharmaceutical compositions, methods of treating or preventing cardiac dysfunction, methods of enhancing cardiac function, and identifying mif inhibitor
BR0201974A (en) Pharmaceutical composition for treating sleep disorders
BRPI0409699A (en) methods of inducing the diuretic effect, inducing, maintaining or restoring the diuretic effect of a non-adenosine modifying diuretic, maintaining, restoring or improving renal function in a patient, inducing diuresis, preventing the onset of renal impairment in a patient with fluid or CHF overload, treating CHF patients and improving overall health outcomes, pharmaceutical composition and uses
BRPI0410374A (en) pharmaceutical composition comprising valsartan

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.